Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE)
Yazar
Skoneczna, Iwona Anna
Tannock, Ian
Fizazi, Karim
Ivanov, Sergei
Karlsson, Camilla Thellenberg
Flechon, Aude
Orlandi, Francisco Jorquera
Gravis, Gwenaelle
Matveev, Vsevolod B.
Bavbek, Sevil E.
Gil, Thierry
Viana, Luciano S.
Aren, Osvaldo Rudy
Karyakin, Oleg
Elliott, Tony
Birtle, Alison J.
Magherini, Emmanuelle
Hatteville, Laurence
Tombal, Bertrand
Rosenthal, Mark
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]